About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
BridgeBio Pharma, Inc. (BBIO): Insider Trades and Fund Holdings
In the past 12 months, BridgeBio Pharma, Inc. insiders reported no open-market purchases and 11 sales worth $28.3M; 11 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Sep 29, 2026CongressRep. Gilbert Ray Cisneros, Jr. partial sell $1K–$15K
- Sep 17, 2026Insider saleCEO Neil Kumar sold $690,848 under a 10b5-1 plan
- Aug 19, 2026Insider saleCEO Neil Kumar sold $840,257 under a 10b5-1 plan (2 days after: signed a material agreement)
- Aug 19, 2026Planned saleKUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 (director, officer) filed notice to sell about $2.5 million around Aug 19, 2026
- Aug 18, 2026Insider saleCEO Neil Kumar sold $2.9 million under a 10b5-1 plan (1 days after: signed a material agreement)
- Aug 18, 2026Planned saleNEIL KUMAR (director, officer) filed notice to sell about $2.8 million around Aug 18, 2026
- Aug 17, 2026NewsCompany reported: Signed a material agreement
- Aug 17, 2026Planned saleRANDAL SCOTT (director) filed notice to sell about $1.7 million around Aug 17, 2026
- Jul 30, 2026Insider saleCAO Maricel Apuli sold $160,120 under a 10b5-1 plan
- Jul 9, 2026Insider saleDirector Jennifer E. Cook sold $13.2 million under a 10b5-1 plan
- Jul 9, 2026Insider saleDirector Andrea Ellis sold $1.4 million under a 10b5-1 plan
- Jun 30, 2026FundBridgewater Associates added 73% in Q2 2026 (13F filed Aug 14, 2026)
- Jun 30, 2026FundViking Global Investors cut 16% in Q2 2026 (13F filed Aug 14, 2026)
- Jun 30, 2026FundRenaissance Technologies added 134% in Q2 2026 (13F filed Aug 13, 2026)
- Jun 24, 2026Insider saleDirector Jennifer E. Cook sold $2.6 million under a 10b5-1 plan
- Jun 23, 2026Insider saleDirector Hannah Valantine sold $150,580 under a 10b5-1 plan
- Jun 23, 2026Insider saleDirector Jennifer E. Cook sold $150,580 under a 10b5-1 plan
- Jun 22, 2026Insider saleDirector Hannah Valantine sold $190,944 under a 10b5-1 plan
- Jun 15, 2026Insider saleDirector Jennifer E. Cook sold $6 million under a 10b5-1 plan
- May 11, 2026CongressRep. Gilbert Ray Cisneros, Jr. buy $1K–$15K
- Apr 29, 2026CongressRep. Gilbert Ray Cisneros, Jr. buy $1K–$15K
- Mar 19, 2026CongressRep. Gilbert Ray Cisneros, Jr. buy $1K–$15K
- Mar 18, 2026CongressRep. Gilbert Ray Cisneros, Jr. buy $1K–$15K
- Mar 3, 2026CongressRep. Gilbert Ray Cisneros, Jr. buy $1K–$15K
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 21, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 21 | Neil KumarCEO | ▼ SELL10b5-1 | $691K |
| Aug 20 | Neil KumarCEO | ▼ SELL10b5-1 | $2.89M |
| Aug 20 | Neil KumarCEO | ▼ SELL10b5-1 | $840K |
| Aug 3 | Maricel ApuliCAO | ▼ SELL10b5-1 | $160K |
| Jul 13 | Jennifer E. CookDirector | ▼ SELL10b5-1 | $13.2M |
| Jul 13 | Andrea EllisDirector | ▼ SELL10b5-1 | $1.44M |
| Jun 24 | Jennifer E. CookDirector | ▼ SELL10b5-1 | $2.60M |
| Jun 24 | Hannah ValantineDirector | ▼ SELL10b5-1 | $191K |
| Jun 24 | Hannah ValantineDirector | ▼ SELL10b5-1 | $151K |
| Jun 24 | Jennifer E. CookDirector | ▼ SELL10b5-1 | $151K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Neil Kumar | CEO | 0 | $0 | 3 | $4.42M |
| Maricel Apuli | CAO | 0 | $0 | 1 | $160K |
| Jennifer E. Cook | Director | 0 | $0 | 4 | $21.9M |
| Andrea Ellis | Director | 0 | $0 | 1 | $1.44M |
| Hannah Valantine | Director | 0 | $0 | 2 | $342K |
Trades by members of Congress
Reported under the STOCK Act. Amounts are ranges from the form. All Congress trades →
| Filed | Member | Type | Amount |
|---|---|---|---|
| Oct 12 | ▼ PARTIAL SELL | $1K–$15K | |
| Jun 8 | ▲ BUY | $1K–$15K | |
| May 8 | ▲ BUY | $1K–$15K | |
| Apr 7 | ▲ BUY | $1K–$15K | |
| Apr 7 | ▲ BUY | $1K–$15K | |
| Apr 7 | ▲ BUY | $1K–$15K |
Buybacks and executive pay
BridgeBio Pharma, Inc. spent $48.3 million buying back its own shares in 2025.
| Year | CEO pay reported | CEO pay "actually paid" | Value of $100 invested |
|---|---|---|---|
| 2025 | $14.9M | $75.4M | n/a |
| 2024 | $15.6M | −$2.66M | n/a |
| 2023 | $12.2M | $70.1M | n/a |
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
A All 11 insider trades reported on time. How it is graded
Tracked funds that report BBIO
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Viking Global Investors | 9,949,219 | $741.0M | ▼ −16.0% |
| Renaissance Technologies | 856,846 | $63.8M | ▲ +134.3% |
| Bridgewater Associates | 448,143 | $33.4M | ▲ +72.7% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →